Previous 10 | Next 10 |
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista ® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory...
2024-05-24 12:12:17 ET Summary Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. Th...
2024-05-22 16:31:48 ET Summary Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuti...
2024-05-07 09:15:00 ET Summary Bausch Health Companies stock experienced a significant drop after posting its first-quarter results, missing expectations by 13 cents. The company's debt maturity profile raises concerns for investors, with a large amount of debt maturing in 2025 an...
2024-05-06 11:12:29 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Bausch + ...
2024-05-02 04:42:01 ET Summary Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headac...
2024-05-01 13:38:09 ET Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Conference Call May 01, 2024, 08:00 ET Company Participants George Gadkowski - VP, IR & Business Insights Brent Saunders - Chairman & CEO Sam Eldessouky - EVP & CFO Confere...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Revenue of $1.099 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP) 1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency 1 Basis Compared to the First Quarter of 2023, Driven by Growt...
2024-04-30 12:15:22 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Bausch + Lomb reports positive study results for Blink NutriTears Emergent ...
News, Short Squeeze, Breakout and More Instantly...
Bausch + Lomb Corporation Company Name:
BLCO Stock Symbol:
NYSE Market:
Bausch + Lomb Corporation Website:
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to dis...
New Online Resource, KnowYourDryEye.com, Aims to Increase Awareness and Education Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today shared results from the company’s inaugural State of Dr...
Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the pre...